Clinical Trials Logo

SARSCoV2 Convalescent Plasma clinical trials

View clinical trials related to SARSCoV2 Convalescent Plasma.

Filter by:
  • No longer available  
  • Page 1

NCT ID: NCT04374370 No longer available - COVID Clinical Trials

SARSCoV2 (COVID-19) Convalescent Plasma (CP) Expanded Access Protocol (EAP)

Start date: n/a
Phase:
Study type: Expanded Access

Convalescent plasma has been administered to treat different infectious diseases previously with some success. There is currently no approved and proven treatment options available for the novel coronavirus disease (COVID-19 virus). Some early data has shown a potential benefit in treating hospitalized patients who have tested positive for COVID-19 with convalescent plasma infusions of fresh plasma donated by fully recovered COVID-19 patients. The antibodies present in the recovered patients' plasma may be of benefit in helping critically ill and infected patients recover from the COVID-19 virus.